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Microenvironment and Immunology
Osteopontin Shapes Immunosuppression in the
Metastatic Niche
Sabina Sangaletti1, Claudio Tripodo2, Sara Sandri1, Ilaria Torselli1, Caterina Vitali1, Chiara Ratti1, Laura Botti1,
Alessia Burocchi1, Rossana Porcasi2, Andrea Tomirotti1, Mario P. Colombo1, and Claudia Chiodoni1
Abstract
The matricellular protein osteopontin (OPN, Spp-1) is widely associated with cancer aggressiveness when
produced by tumor cells, but its impact is uncertain when produced by leukocytes in the context of the tumor
stroma. In a broad study using Spp1/ mice along with gene silencing in tumor cells, we obtained evidence of
distinct and common activities of OPN when produced by tumor or host cells in a spontaneously metastatic
model of breast cancer. Different cellular localization of OPN is associated with its distinct activities, being
mainly secreted in tumor cells while intracellular in myeloid cells. OPN produced by tumor cells supported their
survival in the blood stream, whereas both tumor- and host-derived OPN, particularly from myeloid cells,
rendered themetastatic site more immunosuppressive. Myeloid-derived suppressor cells (MDSC) expanded with
tumor progression at both primary and lung metastatic sites. Of the expanded monocytic and granulocytic cell
populations ofMDSCs, themonocytic subset was the predominant source of OPN. In Spp1/mice, the inhibition
of lung metastases correlated with the expansion of granulocyte-oriented MDSCs. Notably, monocytic MDSCs in
Spp1/mice were less suppressive than their wild-type counterparts due to lower expression of arginase-1, IL6,
and phospho-Stat3. Moreover, fewer regulatory T cells accumulated at the metastatic site in Spp1/mice. Our
data ﬁnd correlation with lung metastases of human mammary carcinomas that are associated with myeloid
cells expressing OPN. Overall, our results unveiled novel functions for OPN in shaping local immunosuppression
in the lung metastatic niche. Cancer Res; 74(17); 4706–19. 2014 AACR.
Introduction
Despite the advances in tumor prevention, early diagno-
sis, and therapeutic treatments, breast cancer remains one
of the leading causes of death among women, mostly
because of its predisposition to metastasize to distant sites,
such as lungs, liver, brain, and bones. Much effort has been
dedicated to the identiﬁcation of molecular mechanisms
conferring metastatic advantage to speciﬁc neoplastic
clones so as to target the relevant pathways. Most of these
pathways are also necessary for the local invasiveness of the
primary tumor, and therefore their targeting may represent
an appealing approach to contrast both aspects at the same
time.
Besides genetically altered cancer cells, a tumor mass
comprises a variety of normal cells that actively participate
in tumor progression, including the metastatic process.
Tumor and stromal cells produce the extracellular matrix
(ECM), composed of structural proteins, such as collagens
and ﬁbronectin, and proteins that regulate cell function and
their interaction, such as osteopontin (OPN, Spp-1), throm-
bospondin, SPARC (secreted protein acidic and rich in
cysteine), and others, collectively referred to as matricellular
proteins. These molecules are generally highly expressed
during development, poorly in steady-state condition of
adult tissues, whereas readily upregulated in wound healing
and tissue remodeling. Matricellular proteins modulate sev-
eral cellular processes, such as cell adhesion and migration,
ECM deposition, cell survival, and proliferation (1). All these
processes are also required for primary tumor growth and
metastasis, in which matricellular proteins are often aber-
rantly expressed.
Among matricellular proteins, elevated OPN expression has
been correlated with poor survival of patients with cancer with
different tumor histotypes (2–4). Accordingly, clinical studies
have shown high OPN plasma concentration in patients with
metastatic tumors compared with normal samples, especially
in breast cancer (5, 6). OPN protumoral and prometastatic
activities have been demonstrated inmice and humans (1, 7, 8)
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through themodulation of tumor cell migration, adhesion, and
invasion (9–12).
Nevertheless, the comprehension of molecular mechanisms
behind OPN functions in cancer remains far from complete
(13). Most studies were centered on OPN produced by tumor
cells, whereas only few have focused on OPN produced by the
host (14–16), moreover without considering the metastatic
setting.
This study, designed to dissect the role of OPN produced by
either the tumor or the host in the context of breast cancer,
provided the ﬁrst evidence of OPN tuning the immunosup-
pressive microenvironment of the metastatic niche.
Materials and Methods
Cell line and mice
The 4T1 cell line (CRL-2539; LGC-Promochem) was derived
from a murine spontaneous mammary carcinoma arising in a
BALB/cfC3H mouse (17). BJMC3879 is a mammary adenocar-
cinoma developed in a BALB/c female upon inoculation into
the inguinalmammary glands ofmousemammary tumor virus
(MMTV; refs. 18, 19) and was kindly provided by Dr. Shibata
(Osaka Medical College, Osaka, Japan). Female BALB/c mice,
8-week-olds, were purchased from Charles River Laboratories.
C57BL/6 spp1/ mice (B6.129S6(Cg)-Spp1tm1Blh/J) were
obtained from The Jackson Laboratory and backcrossed on
BALB/c background for 10 generations. Mice were maintained
at the Fondazione IRCCS Istituto Nazionale Tumori (Milan,
Italy) under standard conditions according to the institutional
guidelines. All in vivo procedures were approved by the Insti-
tute Ethical Committee for animal use.
OPN gene silencing
Stable OPN gene silencing was obtained with the BLOCK-iT
Pol II miR RNAi Expression Vector Kit from Invitrogen (see
Supplementary Data for details and silencing sequences);
Western blot analysis and ELISA on cell supernatants con-
ﬁrmed protein downmodulation (see Supplementary Data),
whereas immunohistochemistry was performed on parafﬁn-
embedded sections of primary tumor samples to conﬁrm
in vivo downmodulation.
In vitro migration, soft-agar colonization, anoikis, and
adhesion assays
The motility of the 4T1 parental and silenced cells was
evaluated in Transwell chambers as previously described (for
more details, see Supplementary Data; ref. 20).
Anchorage-independent growth was determined in 0.3%
agarose (SeaPlaque; FMC BioProducts) with a 0.6% agarose
underlay. Cells (3  103) were plated in semisolid medium
(DMEM 10% FBS plus agar 0.3%) and incubated at 37C in a
humidiﬁed 5% CO2 atmosphere. Colonies were counted under
a microscope, blindly by two operators, after 8 to 12 days.
For an in vitro anoikis assay, 5  105 cells were plated into
6-well tissue-treated plates previously coated or not with
polyhydroxyethylmethacrylate (poly-HEMA; Sigma-Aldrich),
in DMEM supplemented with 10% FBS or 2% FBS. After 20-
hour incubation at 37C, cells were collected, and anoikis
was assessed counting viable cells:dead cells ratio by Trypan
blue staining, blindly by two operators.
An adhesion assay was performed in 6-well plates in which
1G11 endothelial cells (a kind gift of Dr. Vecchi, Humanitas,
Milan, Italy) were previously seeded 48 hours before (24 þ 24
hours in the presence or absence of TNF, at 5 ng/mL to induce
cell activation). 4T1GFP and 4T1silOPN GFP cells (5  104)
were added and let to adhere for 30 minutes; after PBS1x wash,
cells were collected by trypsinization and GFPþ cells were
evaluated by ﬂow cytometry.
In vivo experiments
Parental, silenced, or control cell lines were inoculated
orthotopically in the mammary fat pad (i.f.p.) at a dose of
5  104 cells per mouse or intravenously (i.v.) at a dose of
104 cells per mouse. For BJMC3879, 5  106 cells per mouse
were used. Primary tumor growth was measured once a week
with a caliper, and the volumewas calculated using the formula
d2  D/2, where d and D are the short and long diameters,
respectively.
For micrometastasis evaluation, lungs were removed from
each mouse 28 days after tumor injection, and a clonogenic
assay was performed (see Supplementary Data). For macro-
metastasis evaluation, lungs were removed after intratra-
cheal perfusion with 15% China ink and ﬁxed with Fekete
solution (10% formaldehyde; 5% acetic acid in Et-OH 70%).
Metastases, identiﬁed as white spots, were counted blindly
by two operators. Alternatively, metastases were counted on
H&E (hematoxylin and eosin)-stained lung sessions under
the microscope.
For a lung colonization assay, 4T1 cells or 4T1 silOPN527,
both expressing GFP, were injected i.v. (2 106 cells/mouse)
in BALB/c mice. Peripheral blood leukocytes (PBL) were
drawn at 2, 4, 8, 16, 24, and 48 hours and analyzed by ﬂow
cytometry for the presence of GFPþ CD45.2 cells. For lung
evalution, 1, 3, 4, and 5 days after cells injection, mice were
sacriﬁced, their lungs minced, digested with collagenase/
hyaluronidase solution (STEMCELL Technologies), and ana-
lyzed by ﬂow cytometry.
Histopathologic and immunohistochemical analysis
Samples, ﬁxed in 10% neutral buffered formalin, were
embedded in parafﬁn. Serial sections were cut at 4 mm from
each block and stained with H&E. For immunohistochemical
staining, the sections were dewaxed and rehydrated. After
heat-mediated antigenic retrieval using a pH 9.0 Tris–EDTA
buffer for 30 minutes in thermostatic water bath, the sections
were incubated with 3% hydrogen peroxide for 5 minutes to
quench endogenous peroxidase activity, and for 10 minutes
with protein block (Novocastra, Ltd.). The sections were sub-
sequently incubated with primary antibodies: anti-human/
mouse OPN (dilution, 1:100; R&D Systems, Inc.), anti-P-Stat3
(dilution, 1:200; Acris Antibodies, GmbH), and anti-human
CD68 (dilution, 1:100; Dako). For negative controls, mouse or
rabbit immune sera were used instead of primary antibodies.
Staining was revealed with a polymeric system (Novolink, Max
Polymer Detection System; Novocastra Ltd.) and visualized by
using AECþ High Sensitivity Substrate Chromogen Ready-to-
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use (Dako Cytomation Liquid AEC Substrate Chromogen
System; Dako). Slides were counterstained with hematoxylin
and evaluated under a Leica DM2000 optical microscope.
Double-marker immunoﬂuorescence and confocal
microscopy
For double immunoﬂuorescence, two sequential rounds of
single-marker immunoﬂuorescence were performed using
CD68/OPN and CD68/arginase-1 markers. The sections were
incubated with the ﬁrst primary antibody (OPN or arginase-1)
overnight at 4C in a humidiﬁed chamber, then washed in PBS,
and incubated for 1 hour with an Alexa Fluor 488–conjugated
anti-rabbit antibody (dilution, 1:100) for arginase-1 andwith an
Alexa Fluor 488–conjugated anti-goat secondary antibody
(dilution, 1:100) for OPN. Then, the slides were washed in PBS
and incubated with CD68 for 1 hour, which was revealed using
an Alexa Fluor 568–conjugated anti-mouse Ab (dilution 1:200).
The sections were counterstained with DAPI (DNA stain) for 1
minute and mounted using coverslip with a drop of mounting
medium.
For confocal microscopy analysis, myeloid cells or 4T1
cells were seeded onto poly-D-lysine–coated glasses, let to
adhere, and 2 hours later, ﬁxed with PFA 4%. For intracel-
lular staining of OPN, glasses were sequentially incubated
with 0.1% Triton X-100, 1% BSA, polyclonal rabbit anti-OPN
(Abcam), in 0.1% BSA solution and Alexa Fluor 546 anti-
rabbit secondary antibody. For staining of the endoplasmic
reticulum (ER) concanavalin A (Alexa Fluor 488–conjugated;
Life Technologies) was added as the ﬁnal step. Glasses were
analyzed with a Microradiance 2000 (Bio-Rad Laboratories)
confocal microscope equipped with Ar (488 nm), HeNe
(543 nm), and red laser diode (638 nm) lasers. Confocal
images (512  512 pixels) were obtained using a 20, 0.5 NA
Plan Fluor DIC or 60, 1.4 NA oil immersion lens and
analyzed using ImagePro 7.0.1 software.
FACS analysis
For FACS analysis, primary tumors or lungs were collected
and perfused with DMEM plus 10% FBS, minced, and then
ﬁltered through a 40-mm-pore cell strainer (BD Biosciences).
Red blood cells were removed using ACK lysis buffer (ammo-
nium chloride potassium). Cells were Fc-blocked using CD16/
32 antibody (eBioscience) before staining. The following anti-
bodies were used: CD45.2, Gr-1, CD11b, F4/80, Ly6C, CD11c,
CD4 and CD8, CD44, CD69, and CD62L (all from eBioscience).
For regulatory T cells (Treg) detection, after surface staining for
CD4, cells were ﬁxed, permeabilized, and stained with FoxP3
Ab, following the manufacturer's instructions (eBioscience).
Samples were acquired using a BD LSR II Fortessa instru-
ment and analyzed with FlowJo software (TreeStar). All sam-
ples are analyzed in single; in each experiment, at least three to
four samples were analyzed for each group.
Myeloid-derived suppressor cell puriﬁcation and in vitro
suppression assay
Myeloid-derived suppressor cells (MDSC) were puriﬁed
using CD11b-conjugated microbeads (for overall population)
and the Myeloid-Derived Suppressor Cell Isolation Kit (for
separation of the two subsets; Miltenyi Biotec) following the
manufacturer's instructions.
For an in vitro suppression assay, 4  105 na€ve BALB/c
splenocytes were labeledwith carboxyﬂuorescein succinimidyl
ester (CFSE; Sigma-Aldrich) and cocultured with the different
MDSC population at different ratios in the presence of 2mg/mL
of soluble anti-CD3 and 1 mg/mL of anti-CD28 to activate
lymphocytes. Each sample was seeded in triplicate. Prolifera-
tion of CD4 and CD8 T cells was assessed 2 and 3 days later, by
ﬂow cytometry evaluating CFSE dilution in the CD4þ- and
CD8þ-gated populations. Results are shown as the percentage
of proliferated cells.
RNA extraction and qPCR
For qPCR analysis, MDSC subsets and other leukocyte
populations were puriﬁed from the lungs of tumor-bearing
mice, pooling at least 5 mice per group; lungs wereminced and
digested for 45 minutes at 37C in collagenase/hyaluronidase
solution, washed with complete medium, and stained with the
speciﬁc Abs before cell sorting with a FACSAria instrument
(BD Biosciences). Purity of the different population was >99%.
RNA was puriﬁed from TRIzol (Invitrogen)-disrupted
cells by phenol/chloroform extraction followed by loading
onto an RNeasy MINI or MICRO kit (Qiagen). On-column
DNAse treatment was routinely performed. RNA purity
and yield was assessed using NanoDrop. RNA was reverse
transcribed using the High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). qPCR reaction
was prepared using TaqMan Fast Universal PCR Master
Mix and run on a 7900 HT Fast Real-time PCR System
(Applied Biosystems). The following TaqMan probes were
used: Gapdh (Mm99999915_g1), Spp1 (Mm00436767_m1),
Arg-1 (Mm00475988_m1), Nos2 (Mm00440502_m1),
Il6 (Mm00446190_m1), Stat3 (Mm01219775_m1), Vegf
(Mm01281449_m1), and (Mm01178820_m1).
Statistical analysis
For evaluation of lung metastases, data were represented
singularly, and median was shown in the graph; statistical
signiﬁcance was evaluated with the Mann–Whitney test using
Prism 5 software. For all the other experiments, data were
represented asmean SD, and an unpaired two-tailed Student
t test was used for statistical analysis.
Results
RNA interference of OPN expression affects in vitro
and in vivo metastatic phenotype of mammary
adenocarcinoma
RNA interference was used to generate stable OPN-silenced
4T1 mammary cancer cells using three different sequences,
215, 527, and 602 (see Materials and Methods and Supplemen-
tary Data). Efﬁciency of gene silencing was evaluated by
Western blot analysis on cell lysates and by ELISA on cell
supernatants (Supplementary Fig. S1A and S1B); as a control
we used cells transduced with nontarget sequence (4T1 NT).
Initial in vitro and in vivo experiments were conducted with all
the three silenced clones, and with clone 527 thereafter
(4T1silOPN527).
Sangaletti et al.
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Migratory ability of silenced clones assessed across Transwell
membranes was signiﬁcantly inhibited in comparisonwith that
of parental and NT control (Supplementary Fig. S1C). Consis-
tently, OPN neutralization by an anti-OPN antibody markedly
diminished the migration of 4T1 wild-type (WT) and control
cells (Supplementary Fig. S1D). Anchorage-independent
growth, evaluated in soft agar, showed no difference in the
number of colonies (Supplementary Fig. S1E, top), despite a
reduction in size of 4T1silOPN527 colonies (bottom). No dif-
ference was detected in proliferation rate in vitro (not shown).
OPN-silenced 4T1 cells and their WT and NT control coun-
terparts injected into the mammary fat pad formed primary
tumors with similar size and onset (Fig. 1A). Immunohisto-
chemical analysis of OPN expression on tumor nodules
Figure 1. OPN silencing in tumor
cells reduces their metastatic
potential, affecting survival in lung
circulation and lung colonization.
A, primary tumor growth of OPN-
silenced 4T1 cells in comparison
with parental and NT cells. Tumor
volume is measured by caliper
and calculated as (d2  D)/2.
The graph is a pool of four different
experiments, each performed with
7 mice per group. B, OPN staining
in primary tumor samples from
4T1 parental and OPN-silenced
cells. C, spontaneous lung
micrometastases after orthotopic
injection i.f.p., evaluated by a
clonogenic assay, of 4T1 cells
OPN-silenced, WT, and control
NT. A pool of four experiments is
shown; 5–7 mice per group for
each experiment. D, representative
images of lungs from 4T1-bearing
mice, either WT or OPN-silenced.
E, experimental lung
macrometastases upon i.v.
injection, counted after ink
perfusion, of 4T1 cells OPN-
silenced, WT, and control NT. A
pool of two experiments is shown;
5–7 mice per group for each
experiment (repeated at least three
times). F, in vitro adhesion
experiment of 4T1GFP and
4T1silOPNGFP tumor cells on
endothelial cells (1G11) either
resting or upon 24 hours TNF
activation. Cells were plated in
triplicate; experiment performed
twice. G, anoikis in vitro assay of
4T1 cells OPN-silenced and WT
control; cells were seeded in
triplicates onto poly-HEMA–
treated plates in the presence of
2% or 10% FBS; experiment was
performed twice. H, PBL (left)
and lung parenchyma (right)
colonization at early time points
after i.v. injection of 2  106
4T1GFP and 4T1silOPNGFP tumor
cells. Lung tissue was digested,
and cell suspension from lungs and
PBL analyzed by FACS for GFPþ
cells; cells were gated on the
CD45.2 population; experiment
was performed three times, with
three samples per group for each
time point. , P < 0.05; , P < 0.01;
, P < 0.005.
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conﬁrmed efﬁcient OPN downmodulation in the case of
silencing (Fig. 1B). On the other hand, the evaluation of
spontaneousmetastases showed that OPN-silenced 4T1 clones
have signiﬁcantly reduced metastatic capacity (Fig. 1C and D
and Supplementary Fig. S1F).
Injection of tumor cells directly into the blood stream
bypasses the initial steps of the metastatic process such as
tumor detachment and cell intravasation. Intravenous injec-
tion of 4T1silOPN527 cells induced signiﬁcantly less metas-
tases to the lungs than OPN-proﬁcient controls, indicating
that tumor-derived OPN is required for a late step of
metastasis, from circulation to the seeding into the target
organ (Fig. 1E). Consistently, other OPN-silenced clones
were also less metastatic upon i.v. injection (Supplementary
Fig. S1G).
Tumor cell–produced OPN was not required for adherence
to resting or activated endothelial cells as tested in vitro
(Fig. 1F). However, the ability to survive in the bloodstream
was different, in agreement with the known activity of OPN-
protecting cancer cells from apoptosis (21): 4T1silOPN527 cells
showed increased cell death than parental 4T1 cells when
cultured in nonadherent condition in vitro (Fig. 1G) and at early
time points after in vivo i.v. inoculation. Indeed, when we i.v.
injected GFP-expressing 4T1 cells and evaluated their numbers
in PBL and lungs at early time points after injection, we found
that GFPþ 4T1silOPN527 cells were fewer in number than
GFPþ parental 4T1 cells in the lungs starting 24 hours after
injection and thereafter. We excluded an uneven number of
cells injected because the amount of GFPþ cells, either OPN-
proﬁcient or -deﬁcient, in PBL was similar at earlier time
points (2, 4, 8, and 16 hours; Fig. 1H).
Host-derivedOPNcontributes to themetastatic spreadof
breast cancer polarizing myeloid cells toward
immunosuppression
Once demonstrated that tumor-derived OPN works mainly
autocrinally, conferring survival advantage in anoikis condi-
tions, we tested whether or not host-produced OPN contrib-
uted to metastasis. This possibility stems from the reported
activity of OPN in skewing macrophages to a M1 phenotype
through downmodulation of IL10 and upregulation of IL12
production (22), and could, theoretically, negatively affect
tumor growth and metastasis. Therefore, we injected 4T1 cells
in WT and Spp1/ mice and, to exclude any masking effect
exerted by the high endogenous expression of OPN by 4T1
parental cells, 4T1silOPN527 cells were also included.
4T1 cells formed signiﬁcantly lower numbers of metastases
in Spp1/ mice than WT counterparts (Fig. 2A), despite
similar primary tumor growth (not shown), demonstrating
that host-derived OPN also contributes to metastasis. The
lower metastatic ability of 4T1 cells in Spp1/ mice was
conﬁrmed in the case of i.v. injection, indicating that host-
derived OPN is required at later stages of metastasis directly at
the seeding organ (Fig. 2B). The paucity of 4T1silOPN527
metastasis in WT mice did not allow us to detect further
decrease in metastasis in Spp1/ animals (Fig. 2A).
Whether accessory cells involved in breast cancer metasta-
sis, such as macrophages (23), MDSC (24–26), and T cells
(27, 28),might useOPN to favor themetastatic process remains
unknown.
First, we analyzed the MDSC population, identiﬁed as
CD11bþ/Gr-1þ cells in the mouse, because of their reported
role in 4T1 breast cancer metastasis (25, 29, 30) and of their
huge expansion in the lungs of tumor-bearing mice, where
they represent 70% to 80% of the inﬁltrating leukocytes.
Overall, the number of CD11bþ/Gr-1þ cells was not different
in lungs of Spp1/ and WT tumor-bearing mice, whereas
splitting the myeloid population into the two subsets of
Gr-1high (granulocytic) and Gr-1int/low (monocytic) cells
highlighted a signiﬁcant change in their ratio: expanded
Gr-1high subset in Spp1/ mice at the expense of the
Gr-1int/low, more suppressive, one (Fig. 2C). Such difference
was tumor induced because lungs and spleens of tumor-free
mice showed a similar ratio between the two subsets
regardless of the Spp1 genotype (Supplementary Fig. S2A).
As OPN may have a role in protection from apoptosis, we
determined whether lung MDSC from Spp1/ tumor
bearers had a different apoptotic rate than their WT coun-
terparts. AnnexinV/PI ﬂow cytometry did not show strain
difference for either subset (data not shown).
Notably, the Gr-1int/low subset expressed Spp1 at a much
higher level than theGr-1high population, as tested by qPCRand
conﬁrmed by double immunoﬂuorescence, showing OPN
expression mainly in CD68þ cells with monocytic appearance
(Fig. 2D). This result raised the question ofwhetherOPNplays a
role in MDSC immunosuppression.
An in vitro suppressive assay, performed using the puriﬁed
Gr-1high and Gr-1int/low subsets, showed that Gr-1int/low cells
from WT mice were signiﬁcantly more suppressive than their
Spp1/ counterparts against CD3/CD28-activated CD8 and
CD4 T cells (Fig. 3A and Supplementary Fig. S2B). As expected,
the suppressive ability of Gr-1int/low cells was higher than that
of the Gr-1high subset.
To better characterize the Gr1high and Gr-1int/low subsets
from metastatic lungs of Spp1/ and WT mice, qPCR was
performed on genes relevant for MDSC function. Arginase-1
(Arg-1), Tgfb1, Il6, and Stat3 were higher in the Gr-1int/low than
in the Gr1high subsets; vice versa,Nos2was higher in the Gr1high
than in theGr-1int/low cells (Fig. 3B). Strikingly,Arg-1 expression
in the Gr-1int/low subset was repressed in Spp1/ mice,
supporting the idea of a less suppressive phenotype we
observed in the absence of OPN (Fig. 3A). A similar trend,
although not statistically signiﬁcant, was observed for Stat3,
Il6, Tgfb1, and Vegf, with their expression reduced in Spp1/
mice. In metastatic lungs, double immunoﬂuorescence anal-
ysis conﬁrmed the colocalization of OPN and arginase-1
(Fig. 3C), whereas IHC for phospho (P)-STAT3 stained only
cells with a monocytic appearance, which was represented
more in WT than Spp1/ mice (Supplementary Fig. S3).
To test whether OPN from MDSC was truly relevant for
the metastatic spread of 4T1 cells, coinjection experiments
were performed. WT, but not Spp1/, MDSC isolated from
the spleen of tumor-bearing mice increased lung metastases
when coinjected with 4T1 cells (Fig. 3D), and even more
signiﬁcantly when coinjected into Spp1/ hosts. No effect
was observed when bone marrow–derived macrophages
Sangaletti et al.
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from either Spp1/ or WT mice were partners of the
coinjection (not shown).
These results indicate that myeloid cell–produced OPN
favors the metastatic spread of 4T1 carcinoma.
Host-derived OPN molds immunosuppression at the
metastatic site
To test whether host OPN deﬁciency affected other leuko-
cyte populations inﬁltrating the lungs of tumor-bearing mice,
we performed multiparametric FACS analysis comparing
Spp1/ and WT mice. No substantial difference in total
CD11bþ cells (conﬁrming the previous data) and overall
CD4þ T cells and CD8þ T cells was detected. Nevertheless,
intracellular staining for the FoxP3 transcription factor, iden-
tifying regulatory T cells (Treg), showed a reduced frequency
of CD4þFoxP3þ cells in Spp1/ mice (Fig. 4A), a result
conﬁrmed by IHC analysis on lung sections (Fig. 4B). A reduced
Treg number was associated with increased frequency of
CD4þ-activated T cells (detected as CD44þCD69þ and
CD62LlowCD69þ cells) in Spp1/ mice (Supplementary Fig.
S4A and S4B). On the same leukocyte populations, sorted from
the lungs of tumor-bearingmice,we evaluated by qPCR the level
of Spp1 expression to assess whether other cells, besidesMDSC,
express it. We conﬁrmed a high Spp1 level in the Gr-1int/low
MDSC subset, whereas other leukocytes express it at a much
lower level (Supplementary Fig. S4C).
Altogether, these data point to a role of host-derived OPN,
mostly frommonocytic MDSC, in tuning the immunosuppres-
sive microenvironment of the metastatic lung niche.
Tumor-produced OPN contributes to local
immunosuppression
We tested whether tumor-produced OPN contributed to
molding the local immunosuppression in lung metastases. No
signiﬁcant differences were observed in leukocytes distribu-
tion and ratio in 4T1silOPN527 versus 4T1 metastatic lungs;
Figure 2. Host-derived OPN
contributes to lung metastasis,
affecting MDSC polarization.
A, spontaneous lung
micrometastases, evaluated by the
clonogenic assay, of WT and
OPN-silenced 4T1 cells in WT and
Spp1/ mice after orthotopic
injection i.f.p. A pool of two
experiments is shown and
experiment was repeated four
times for 4T1 WT with 6 to 7 mice
per group and twice for OPN-
silenced cells. B, experimental lung
micrometastases of WT and
OPN-silenced 4T1 cells in WT and
Spp1/ mice after i.v. injection.
One representative experiment
out of three was performed; 6
to 7 mice per group. C, MDSC
polarization in lungs and spleen of
4T1 tumor-bearing mice, either WT
or Spp1/. Mean andSDof 5mice
per group is shown. The
experiment was repeated four
times. D, expression of OPN
assayed by qPCR in the MDSC
subsets (Gr1high andGr1int/low) from
lungs of WT and Spp1/ tumor-
bearing mice (left). The WT Gr-1high
MDSC subset was used as a
reference (¼1). Mean of three
samples per group; each sample is
a pool of 4 to 5 mice; experiment
was repeated three times. Right,
immunoﬂuorescence for OPN (red)
and for the monocytic marker
CD68 (green) in the lungs of WT
mice. , P < 0.05; , P < 0.01;
, P < 0.005.
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MDSC number and ratio, as well as Treg number, were similar
in lungs of mice bearing either parental or OPN-silenced 4T1
tumors (not shown). However, the analysis of in vitro suppres-
sive activity of MDSC isolated from the lungs of mice bearing
4T1 cells or their OPN-silenced counterpart showed less sup-
pression of T-cell proliferation in caseGr1int/low cells were from
mice bearing 4T1silOPN527 tumors (Fig. 5A). Accordingly, this
subset expressed lower level of Arg1 and Nos2 than its
Figure 3. OPN molds the suppressive phenotype of MDSC, contributing to the metastatic potential of 4T1 cells. A, in vitro immunosuppressive activity of
the two subsets of MDSC from the lungs of WT and Spp1/ tumor-bearing mice on CD4 and CD8 T-cell proliferation; the suppressive activity was
evaluated 3 days later. Samples are in triplicates. The experiment was performed three times, with overlapping results. B, expression of Arg-1, Nos2, Stat3, Il6,
Vegf, and Tgfb1 in the MDSC Gr1high and Gr1int/low subsets by qPCR; the WT Gr-1high MDSC subset was used as a reference (¼1). Samples are in duplicates;
each one is a pool of 4 to 5 mice; one experiment is shown, out of the two performed. C, immunoﬂuorescence showing colocalization of arginase-1 (green) and
OPN (red) expression inmyeloid cells in lungs ofWT tumor-bearingmice. D, in vivo coinjection experiment of tumor cells with CD11bþ cells puriﬁed from tumor-
bearing mice (either WT or Spp1/) into WT and Spp1/ mice. Cell mix (1:1) was injected i.f.p. Experiment was repeated twice.
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counterpart isolated from 4T1 WT tumor-bearing mice
(Fig. 5B). No different expression for Il6, Vegf, Tgfb1, and Stat3
was detected (not shown).
Considering that 4T1silOPN cells produce less metastases
than the 4T1 counterpart, their contribution in terms of
immunomodulatory factors should be reduced, explaining
the lower immunosuppressive capacity of myeloid cells
inﬁltrating these metastatic lungs. Either alternatively
or concomitantly, the downmodulation of OPN expression
in tumor cells may alter their secretion of immunosuppres-
sive factors. This was indeed the case, at least for Vegf and
Il6 that were less expressed in OPN-silenced tumor cells
(Fig. 5C).
Different form and cellular localization of OPN may
account for the various activities of tumor- and host-
derived OPN
Although tumor-derived OPN contributes to shaping MDSC
immunosuppressive activity, 4T1 cells, fully competent for
OPN production, are not able to compensate for the absence
of OPN in the host, and when injected into Spp1/mice, these
cells show severely impaired metastatic ability.
To explain such observation, we considered the recently
described intracellular form of OPN (iOPN), which has been
found enriched in cells of the monocytic lineage (31), and we
hypothesized that tumor cells produce OPN mainly in the
secreted form (sOPN),whereasmyeloid cells in the intracellular
form.
We evaluated the amount of sOPN in the supernatant from
tumor andmyeloid cells in relation to their OPN expression by
qPCR. One million 4T1 tumor cells secreted roughly 1 mg/mL/
24 hours of OPN, which was almost undetectable in the
supernatant from myeloid cells (Fig. 6A). Although gene
expression data by qPCR conﬁrmed the trend of amuch higher
level in tumor cells than in myeloid cells, the ratio is not so
striking as in the ELISA assay (300 vs. 10,000 in qPCR and
ELISA, respectively; Fig. 6B). In addition, considering that qPCR
data account for both sOPNand iOPN, it is likely thatmostOPN
from tumor cells is secreted, whereas that frommyeloid cells is
retained in the cell. This interpretation was conﬁrmed by
confocal analysis showing that in tumor cells OPN was mainly
cytoplasmic and colocalized with concanavalin A (staining
ER), whereas in monocytic myeloid cells, OPN remained con-
ﬁned to speciﬁc spots under the cellular membrane, as
reported in ref. 31, and not localized in the ER (Fig. 6C).
The requirement for host-produced OPN in lung
metastasis is not restricted to the 4T1 tumor model
To assess whether host-derived OPN favors metastatic
dissemination of mammary carcinomas other than the
4T1 model, the BJMC3879 adenocarcinoma (18, 19), another
spontaneously metastasizing BALB/c breast tumor, was
tested. Along with tumor progression, BJMC3879 expanded
CD11bþ/Gr-1þ cells in PBL, spleen, and lungs (data not shown)
and, phenocopying 4T1 cells, produced similar primary tumors
but less lung metastases in Spp1/ thanWTmice (Fig. 7A–C).
In addition, similar to the 4T1 model, the CD11bþ/Gr-1þ cell
population showed an increase in the Gr-1high fraction in the
absence of OPN (Fig. 7D). These data indicate that the effect of
Figure 4. The absence of OPN
inﬂuences the number of Treg in
lungs of tumor-bearing mice. A,
left, leukocyte inﬁltration in the
lungs of WT or Spp1/ tumor-
bearing mice by multiparametric
FACS analysis with the following
markers: CD45.2, CD11b, Gr-1,
CD4, CD8 (surface), and FoxP3
(intracellular). Cells are shown as
percentage of CD45þ cells. Graph
shows themeanof four samples for
each group; experiment was
performed four times. Right,
examples of FACS plot for the
MDSC subsets (Gr-1high and
Gr1int/low) and Treg (FoxP3þ cells,
gating on CD4þ cells) from the
lungs of WT and Spp1/
tumor-bearing mice. , P < 0.05;
, P < 0.01. B, IHC of FoxP3þ Treg
in lungs of WT and Spp1/ mice
bearing 4T1 tumors.
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Figure 5. Role of tumor-derived
OPN in the modulation of MDSC
activity. A, in vitro suppressive
activity of the Gr-1high and
Gr-1int/low subsets isolated from
the lungs of mice bearing 4T1 WT
and 4T1silOPN tumors. Naïve T
cells were stained with CFSE and
then seeded with scalar doses of
Gr-1high or Gr-1int/low cells in the
presence ofa-CD3 anda-CD8Abs
for stimulation. Suppressive
activity was evaluated 3 days later.
Each sample is in triplicate. Graphs
show mean and SD of the
triplicates. B, real-time PCR for
Arg1 and Nos2 in the Gr-1high and
Gr-1int/low subsets isolated from
the lungs of mice bearing 4T1 WT
and 4T1silOPN tumors. Each
sample is a pool of 7 mice; qPCR
was performed twice on the same
samples. Gr-1high cells from 4T1
WT–bearing mice were used as a
reference (¼1). C, real-timePCR for
Vegf and IL-6 in 4T1and4T1silOPN
cells in comparison toGr-1high cells
from 4T1WT–bearing mice was
used as a reference. The
experiment was performed in
triplicate and repeated twice
(, P < 0.05; , P < 0.01).
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host-produced OPN in breast cancer lung metastasis is not
restricted to the 4T1 tumor model.
OPN stains myeloid cells in lung metastasis from breast
cancer patients
To assess whether our ﬁnding in the mouse models has any
clinical correlation, we evaluated the expression of OPN in lung
metastases from 5 patients with breast cancer undergoing
metastasectomy (see Supplementary Table S1 for clinical
parameters). In the cases evaluated, OPN expression was
detected in cells with monocytic morphology inﬁltrating met-
astatic cancer foci (Fig. 7E). Double immunoﬂuorescence
analysis using Abs for human OPN and the monocytic/mac-
rophagic marker CD68 conﬁrmed the myeloid/monocytic
nature of OPN-expressing cells inﬁltrating breast carcinoma
lung metastases (Fig. 7F).
Discussion
Tumor development and progression require a suitable
microenvironment in which tumor cells conscript and corrupt
normal resident cells, such as ﬁbroblasts and endothelial cells,
while recruiting accessory cells from the bone marrow toward
their needs (32). Besides cellular elements, tumor stroma
comprises the ECM, a complex network of macromolecules
with different physical, biochemical, and biomechanical prop-
erties, also relevant for tumor progression andmetastasis (33).
Among matricellular proteins, OPN has been extensively stud-
ied as a tumor cell product conferringmigratory, adhesive, and
growth capacity. Whether OPN produced by stromal cells
contributes to tumor progression and metastasis has not been
deﬁned. Here, we have dissected the role of OPN in breast
cancer primary tumor growth and metastasis when its pro-
duction was either tumor or host derived. Whereas our data
substantially agree with the available literature in ﬁnding
tumor-derived OPN prometastatic, the effect on primary
tumor was negligible in our models, while rather relevant in
other transplantable tumors (34–37). The effects of OPN
inhibition in tumor cells have been investigated mainly in vitro
testing cell adhesion, migration, invasion throughMatrigel (34,
35, 37) or cell proliferation (38). Silencing OPN in 4T1 tumor
cells, we obtained concordant inhibition of cell migration and
invasion but no effect in cell proliferation and adhesion to
different substrates (data not shown). Such in vitro effects,
however, found little correlation with the in vivo metastatic
activity we observed, in which tumor-produced OPN renders
Figure 6. Tumor and myeloid cells
show different cellular localization
of OPN. A, quantiﬁcation of OPN in
the supernatants of 4T1 tumor cells
and of the MDSC subsets by
ELISA. Cells were seeded in 6- or
24-well plates at 106 cells/mL,
in complete medium, and
supernatants recovered at 24 and
48 hours. The ELISA Kit (R&D
Systems) was performed following
the manufacturer's instructions.
Experiment was performed twice
on different supernatant samples.
B, real-time PCR for Spp1
expression on the same samples,
recovering the cells in TRIzol and
extracting RNA as described in
Materials and Methods. The WT
Gr-1int/low MDSC subset at 24
hourswasused asa reference (¼1).
C, confocal analysis of OPN
localization in tumor and myeloid
cells. OPN (red) and concanavalin
A (green) for Golgi and ER staining.
Single and merged channels are
shown.
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the cells intrinsically more resistant to apoptosis while in the
blood stream, rather than favoring detachment from the
primary site or intravasation. Accordingly, we found a similar
antimetastatic effect of OPN silencing, using both intra-mam-
mary fat pad and intravenous injection routes and did not
observe any difference in the epithelial-to-mesenchymal
Figure 7. Host-derived OPN effect
on metastasis is not model
restricted. A, primary tumor growth
of BJMC3879 mammary tumor cell
line (5  106 cells i.f.p.) in WT and
Spp1/ mice. Tumor volume is
measured by caliper and
calculated as (d2 D)/2. The graph
is a pool of two different
experiments; each performed
with 7 mice per group. B, lung
metastases after i.f.p. injection of
BJMC3879 cells in WT and
Spp1/ mice; mice were
sacriﬁced at day 40 to 45 after
tumor injection and lung
metastaseswere evaluatedbyH&E
staining on serial lung sessions,
blindly by two different operators.
The graph is a pool of two
experiments; each performed with
7mice per group. C, representative
images of lungs from WT and
Spp1/ mice injected i.f.p. with
BJMC3879 cells. H&E staining. D,
the Gr-1high and Gr-1int/low subsets
in WT and Spp1/ mice bearing
BJMC3879 mammary tumors.
Graph, representative of one
experiment out of two performed.
E, immunohistochemical analysis
of OPN expression on lung
sessions from patients with breast
cancer (see Supplementary Table
S1 for clinical parameters)with lung
dissemination. OPN stains large
cells with monocytic appearance.
F, double immunoﬂuorescence on
lung sessions from patients with
metastatic breast cancer for OPN
(green) and monocytic marker
CD68 (red). DAPI, blue channel.
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transition (EMT) phenotype between OPN-silenced or WT
primary tumors (not shown). Nevertheless, data showing
smaller soft-agar colonies (Fig. 1D), and smaller metastatic
foci in the lungs of mice injected with OPN-silenced tumor
cells, suggest that OPN might also contribute to lung paren-
chyma colonization.
Here, we provide novel ﬁndings showing that host-derived
OPN, in particular from myeloid cells, molds the immunosup-
pressive microenvironment at the metastatic niche. The met-
astatic potential of mammary tumors was greatly reduced
when the recipient mice were OPN deﬁcient, despite the fact
that tumor was fully competent for OPN production, and
the primary tumor grew unmodiﬁed. The analysis of the
immune microenvironment at the metastatic site (i.e., lungs)
showed that OPN favors the presence of immunosuppressive
leukocytes, and that such leukocytes were less suppressive in
Spp1/ mice. Myeloid cells endowed with suppressive activ-
ity, generally termed MDSC, comprise two main subsets in the
mouse, which can be distinguished by the different expression
of the Gr-1 marker: highly expressed on the most abundant,
and poorly suppressive, granulocytic subpopulation (Gr-1high),
whereas expressed at low to intermediate level in the highly
suppressive monocytic subset (Gr-1int/low). Such MDSC are
massively recruited to both primary tumor and metastatic
lungs in the 4T1 mammary carcinoma (39, 40). We show here
that in Spp1/ mice, the ratio of the two subsets is signiﬁ-
cantly different, with a less abundant Gr-1int/low-suppressive
population (Fig. 2C). Interestingly, OPN expression seems to be
mainly conﬁned to the monocytic subset, suggesting that OPN
may directly contribute to their immunosuppressive pheno-
type. Indeed, when tested for their ability to suppress T-cell
proliferation in vitro, Gr-1int/low cells from lungs of 4T1-bearing
Spp1/ mice were less suppressive than their WT counter-
parts (Fig. 3A). We hypothesize that the different ratio of the
two MDSC subsets in favor of the Gr1high population and the
reduced suppressive activity of the remainingGr-1int/low subset
create a lung microenvironment less permissive to metastasis.
The reduced suppression of spp1/Gr-1int/low cells correlated
with a lower expression of Arg-1, IL6, and Stat3, all marks of
immunosuppression highly expressed in OPN-proﬁcient
MDSC (Fig. 3B). In vivo, coinjection of tumor cells with MDSC
from either Spp1/ or WT mice conﬁrmed that only those
fromWT mice promoted metastasis of 4T1 cells, regardless of
the Spp1 genotype of recipient mice (Fig. 3D). Whether MDSC
are produced or recruited differently from the bonemarrow or
whether they can transdifferentiate locally in relation to Spp1
genotype is currently unknown.
The absence of host OPN seems to affect other aspects of
local immune response in the lung metastatic niche, that is, it
associates with a decrease in the number of Treg and with
enhanced activation of CD4 T cells. Although OPN inﬂuences
MDSC-suppressive activity, it does not modify Treg–mediated
immunosuppression, at least in vitro, according to our unpub-
lished data. Whether the effect on Treg number depends
directly on the different MDSC population in Spp1/ versus
WT mice deserves further investigation.
The MDSC compartment was affected not only by host-
derived but also by tumor-produced OPN (Fig. 5), likely
because OPN-silenced tumors form less metastases and con-
tribute less in producing immunosuppressive factors, such as
VEGF and IL6.
Despite such contribution from tumor-derived OPN, 4T1
cells, fully competent for OPN production, are not able to
compensate their absence in the host, and when injected
into Spp1/ mice show severely impaired metastatic abil-
ity. To explain this datum, we investigated OPN localization
in tumor and myeloid cells. Indeed, other than the soluble
OPN, an intracellular form (iOPN) has been recently iden-
tiﬁed in leukocytes, particularly in cells of the monocytic
lineage (31). Combining dosage of secreted OPN by ELISA
with qPCR expression analysis and confocal microscopy
(Fig. 6), we demonstrate that tumor cells produce OPN
in high amount in the secreted form, localized within the
Golgi apparatus and ER. Differently, in myeloid cells, OPN
is mainly condensed in speciﬁc spots localized in peri-
membrane areas, phenocopying the described iOPN locali-
zation (33).
The newly described role of host-derived OPN in metas-
tasis was corroborated using a different spontaneously
metastatic breast carcinoma model, the BJMC3879 cell line
(41), that formed less spontaneous lung metastases when
injected into Spp1/ mice (Fig. 7A–D). Very few reports
analyzed the role of host-produced OPN in tumor progres-
sion (14, 15, 35). Two reports (14, 15) studied carcinogen-
induced papilloma and cutaneous squamous cell carcinoma
(SCC), induced directly into Spp1/ mice, therefore in
complete absence of OPN in both host and tumors. The
study from Chakraborty and colleagues (35) was the only one
on breast cancer and showed a protumorigenic activity of
host-derived OPN through the induction of oncogenic mole-
cules, such as MMPs and uPA, and of angiogenesis, without
considering the effect on metastasis.
Our demonstration that myeloid-derived OPN contri-
butes to the immunosuppressive environment required for
metastasis opens the question of whether other matricel-
lular proteins may regulate tumor-associated immune
responses and adds a whole new pathway to those involved
in MDSC ﬁtness. Moreover, this study further enforces the
concept that matricellular proteins may produce different
effects at discrete phases of tumor progression, according
to their tumor-intrinsic or microenvironment-associated
expression (42).
Notably, our data ﬁnd clinical correlation in the presence of
myeloid cells producing OPN in lung metastases of human
ductal mammary carcinomas. In these samples, OPN expres-
sion was detected in scattered reactive cells with monocytoid
morphology that were mostly localized within the stroma at
the interface between the metastatic foci and the surrounding
lung parenchyma, suggesting a role in the local events under-
lying constitution of the metastatic niche. The in-depth char-
acterization of OPN-expressing cancer-associated myeloid
populations and their potential biologic/prognostic relevance
in cancer patient cohorts will represent an appealing issue of
investigation.
In conclusion, our work is the ﬁrst to show a role for both
tumor- and host-derived OPN toward metastatic dissemination
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through themodulation of local immunosuppression in the lung
metastatic niche.
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